ANNEXON INC. - COMMON STOCK

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

07 1 2024 19:00:05 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 12 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

20 12 2023 16:27:50 提供 Nasdaq GlobeNewswire

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

20 12 2023 16:10:53 提供 Nasdaq GlobeNewswire

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

20 12 2023 16:08:02 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 12 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

22 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

13 11 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

09 11 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

24 10 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 10 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

10 10 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

19 9 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 9 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

07 8 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

02 8 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

30 7 2023 11:00:00 提供 Nasdaq GlobeNewswire

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

27 7 2023 05:30:00 提供 Nasdaq GlobeNewswire

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

24 5 2023 15:01:00 提供 Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 5 2023 15:01:00 提供 Nasdaq GlobeNewswire